RELB anticorps (AA 393-413)

N° du produit ABIN3029550

Détail du produit anti-RELB anticorps

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Épitope: AA 393-413

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp RELB est non-conjugé

Application: Western Blotting (WB)

Purification: Antigen affinity

Immunogène: Amino acids 393-413 (LPFTYLPRDHDSYGVDKKRKR-human) were used as the immunogen for this RelB antibody (100% mouse homology).

Isotype: IgG

Information d'application

Indications d'application: The stated application concentrations are suggested starting amounts. Titration of the RelB antibody may be required due to differences in protocols and secondary/substrate sensitivity.\. Western blot: 0.5-1 μg/mL

Restrictions: For Research Use only

Stockage

Buffer: 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water

Stock: -20 °C

Stockage commentaire: After reconstitution, the Rel B antibody can be stored for up to one month at 4°C. For long-term, aliquot and store at -20°C. Avoid repeated freezing and thawing.

Détails sur RELB

Antigène: RELB (V-Rel Reticuloendotheliosis Viral Oncogene Homolog B (RELB))

Autre désignation: RelB (RELB Produits)

Synonymes: anticorps shep, anticorps I-REL, anticorps IREL, anticorps REL-B, anticorps XRelB, anticorps relb-A, anticorps GC-rich, anticorps avian reticuloendotheliosis viral (v-rel) oncogene related B, anticorps RELB proto-oncogene, NF-kB subunit, anticorps v-rel avian reticuloendotheliosis viral oncogene homolog B S homeolog, anticorps Relb, anticorps RELB, anticorps relb.S

Sujet: RelB (v-rel reticuloendotheliosis viral oncogene homolog B) is also known as IREL. By RT-PCR and immunocytochemical analyses, Clark et al.(1999) showed that protein expression correlated with dendritic cell activation. NF-kappa-B-inducing kinase is required for osteoclastogenesis in response to pathologic stimuli. Vaira et al.(2008) found that overexpression of RelB, but not RelA, rescued differentiation of mouse Nik -/- osteoclast precursors, indicating that blockade of the alternative NF-kappa-B pathway, rather than the classic pathway, is responsible for the osteoclastogenic defect in the absence of Nik. Using RelB -/- mice, they showed that the protein itself was required for RankL-induced osteoclastogenesis in vitro and for TNF-induced bone resorption in vivo. Both RelB -/- and Nik -/- mice were resistant to tumor-mediated osteolysis. Vaira et al.(2008) concluded that the alternative NF-kappa-B pathway, via RelB, plays an essential and unique role in RankL signaling toward osteoclast development.

UniProt: Q01201

Pathways: Signalisation NF-kappaB, Signalisation RTK